- Investing Ideas
- /
- Hong Kong Pharmaceuticals & Biotech Breakout Stocks
Hong Kong Pharmaceuticals & Biotech Breakout Stocks
Results
11
Stocks where the price continues to rise after more than a year of consistent gains.
11 companies
XtalPi Holdings
Market Cap: HK$37.2b
An investment holding company, engages in the provision of robotics and drug discovery solutions in Mainland China, the United States, and internationally.
2228
HK$9.25
7D
30.1%
1Y
44.8%
Ascletis Pharma
Market Cap: HK$17.1b
A biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China.
1672
HK$17.74
7D
29.7%
1Y
2,037.3%
CStone Pharmaceuticals
Market Cap: HK$13.6b
A biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally.
2616
HK$9.28
7D
32.6%
1Y
603.0%
Abbisko Cayman
Market Cap: HK$10.8b
Engages in the research and development of pharmaceutical products in the People’s Republic of China and the European Union.
2256
HK$16.00
7D
30.1%
1Y
421.2%
Viva Biotech Holdings
Market Cap: HK$5.6b
An investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide.
1873
HK$2.64
7D
42.7%
1Y
428.0%
Antengene
Market Cap: HK$4.5b
A clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally.
6996
HK$6.64
7D
30.2%
1Y
1,044.8%
SinoMab BioScience
Market Cap: HK$4.3b
A biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics in Mainland China and Hong Kong.
3681
HK$3.53
7D
22.1%
1Y
126.3%
Mabpharm
Market Cap: HK$3.1b
A biopharmaceutical company, engages in research, development, production, and commercialization of drugs and biosimilar for cancers and autoimmune diseases in the People’s Republic of China.
2181
HK$0.74
7D
27.6%
1Y
102.7%
JW (Cayman) Therapeutics
Market Cap: HK$2.4b
A clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunotherapy products in the People’s Republic of China.
2126
HK$5.89
7D
21.9%
1Y
303.4%
Lee's Pharmaceutical Holdings
Market Cap: HK$1.3b
An investment holding company, develops, manufactures, markets, and sells pharmaceutical products in the People's Republic of China, Hong Kong, and internationally.
950
HK$2.15
7D
25.0%
1Y
82.2%
CANbridge Pharmaceuticals
Market Cap: HK$777.5m
A biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide.
1228
HK$1.83
7D
35.6%
1Y
617.6%